Product Reports Resources Pricing Login Book a demo

Biocentis

Biotech & Life Sciences · London, United Kingdom · Founded 2021

Genetic insect control solutions for agriculture and health MoreLess

Biocentis is a forward-thinking biotech company focused on pioneering innovative solutions in the realm of biological control. With a mission to create sustainable and environmentally friendly alternatives to traditional pest management, Biocentis harnesses the power of advanced biotechnologies to address some of the most pressing challenges in agriculture and public health.

At the core of Biocentis' work is the development of cutting-edge biological control agents. These agents, derived from natural organisms, are designed to target and manage pest populations in a way that minimizes ecological disruption and promotes biodiversity. By leveraging the latest advancements in genetic engineering, microbiology, and molecular biology, Biocentis creates highly specific and effective biocontrol solutions that offer a safer alternative to chemical pesticides.

Biocentis' product portfolio includes a range of innovative biocontrol agents tailored to various applications. These products are rigorously tested to ensure their safety, efficacy, and environmental compatibility. By integrating these biocontrol agents into pest management strategies, Biocentis helps farmers, public health officials, and other stakeholders reduce their reliance on harmful chemicals and move towards more sustainable practices.

Collaboration and research are fundamental to Biocentis' approach. The company partners with leading research institutions, industry experts, and regulatory bodies to ensure that its solutions are based on the latest scientific knowledge and adhere to the highest standards of safety and efficacy. This collaborative spirit also extends to engaging with local communities and stakeholders to understand their needs and develop tailored solutions that address specific pest management challenges.

Biocentis is committed to ongoing innovation and the continuous improvement of its products and processes. The company invests heavily in research and development, exploring new technologies and methodologies to enhance the performance and sustainability of its biocontrol agents. This commitment to innovation positions Biocentis at the forefront of the biological control industry, driving forward the transition to more sustainable and environmentally responsible pest management practices.

In addition to its focus on product development, Biocentis places a strong emphasis on education and advocacy. The company actively works to raise awareness about the benefits of biological control and the importance of sustainable pest management. Through outreach programs, educational initiatives, and partnerships with advocacy groups, Biocentis seeks to inspire a broader movement towards more eco-friendly agricultural and public health practices.

Ultimately, Biocentis aims to transform the way we approach pest management, offering innovative, effective, and sustainable solutions that protect both human health and the environment. By championing the use of biological control agents and promoting a shift towards more sustainable practices, Biocentis is helping to build a healthier, more resilient future for our planet.

Company overview

Biocentis company information

The essential company record, classifications and operating signals in one place.

Status
Operational
Founded
2021
Headquarters
London, United Kingdom
Employees
25
Open positions
None listed
Dealroom signal
88.7
client focusb2btechnologyDeep Techsub industryBioTechnologysub industryAgriTechbusiness modelManufacturingindustryHealthsectorBiotechnologysectorCrop ProtectionsectorInfections and Infectious DiseasessectorPest ControlsectorSpinoutsectorSustainable Development GoalssectorRegenerative AgriculturesectorClimate Tech

Valuation & funding

Biocentis funding history

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
GRANTOther financing Nov 2025 $6M Wellcome Trust
SEEDEquity / VC Nov 2025 $13M $52M Grantham Foundation · Algebris Investments
SEEDEquity / VC Feb 2023 $0 Neurone · Global Agri-Food Advancement Partnership
SPINOUTOther financing Jan 2021 $0 Imperial College London · College of Medicine and Integrated Health
Showing 4 recorded eventsUnlock the complete deal history →

Financials

Workforce over time

Available workforce history. Financial fields without reported data are omitted.

YearEmployees
2026 25
2025 20
2024 19
2023 15
Company filings, research estimates and Dealroom dataOpen the full financial model →

Growth signals

Biocentis website traffic

Latest recorded traffic for Biocentis is 1.1K monthly website visits, up 511.1% over the last three months. Biocentis's team grew 25% over the past year.

Latest monthly visits1.1K 3-month web change+511.1% 1-year team growth+25%
Monthly website visits32 observations · Nov 2022–Jun 2026
Hover or focus a point to see its exact monthly valueCompare with peers →

Comparisons

Biocentis compared with similar companies

Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.

Showing 8 of the closest matchesCompare every metric →

Talent graph

Biocentis's talent

Book a demo to see the people
Team profiled 7 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Investors

7 investors on Biocentis's cap table

Sourced from Dealroom's funding and investor records. Investor profile links are shown where available.

Seed 5 investors entered at this stage
Neurone
Global Agri-Food Advancement Partnership
Wellcome Trust
Grantham Foundation
Algebris Investments
Other known 2 additional known investors
College of Medicine and Integrated Health
Imperial College London

Global footprint

Where Biocentis has talent and traffic

Workforce by country
5 countries with
team presence
🇮🇹 Italy73.1%
🇬🇧 United Kingdom11.5%
🇺🇸 United States7.7%
🇱🇺 Luxembourg3.9%
🇬🇷 Greece3.9%
5 countries shown

In the news

Latest news about Biocentis

Recent press, funding announcements, and product moves mentioning Biocentis — open to read from the original sources.

See all news

Market sentiment

What the market is saying about Biocentis

An AI-synthesized read of the highest-engagement posts about Biocentis on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Biocentis’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.